亚克隆TP53突变在滤泡性淋巴瘤中常见且预测放射免疫治疗耐药
在S0016试验的滤泡性淋巴瘤标本中,25%诊断标本和27%验证队列存在亚克隆TP53突变(中位等位基因频率0.02)。R-CHOP组中致病性TP53突变与无进展生存期无关(10年PFS 43% vs 44%);无致病性TP53突变患者中,RIT-CHOP较R-CHOP延长PFS(10年PFS 67% vs 44%;HR=0.49;P=.008)。
要点
- 亚克隆TP53突变见于25%诊断FL标本和27%验证队列。
- R-CHOP组中TP53突变与PFS无关(10年PFS 43% vs 44%)。
- 无致病性TP53突变者接受RIT-CHOP较R-CHOP延长PFS(67% vs 44%)。
核心结论
- 亚克隆TP53突变在FL中常见,是与AICDA介导的遗传异质性不同的现象。
- 无可检测亚克隆TP53突变定义了一组特别受益于RIT的人群。
研究设计与样本
- 对已完成临床试验S0016的存档滤泡性B细胞非霍奇金淋巴瘤标本进行检测。
- S0016为3期随机组间试验,比较CHOP联合利妥昔单抗(R-CHOP)与CHOP联合碘-131托西莫单抗(RIT-CHOP)。
主要发现
- 亚克隆TP53突变(中位等位基因频率0.02)见于25%诊断FL标本和27%独立验证队列。
- R-CHOP组中致病性TP53突变与PFS无关(10年PFS 43% vs 44%)。
- 无致病性TP53突变患者中,RIT-CHOP较R-CHOP延长PFS(10年PFS 67% vs 44%;HR=0.49;P=.008)。
- 未发现PFS与AICDA介导异质性程度之间的关系。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in <5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a completed clinical trial, Southwest Oncology Group S0016, a phase 3 randomized intergroup trial of CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) chemotherapy plus R-CHOP (rituximab-CHOP) compared with CHOP chemotherapy plus 131-iodine tositumomab (radioimmunotherapy [RIT]-CHOP). Subclonal TP53 mutations (median allele frequency 0.02) were found in 25% of diagnostic FL specimens and in 27% of a separate validation cohort. In the R-CHOP arm, pathogenic TP53 mutations were not associated with progression-free survival (PFS) (10-year PFS 43% vs 44%). In contrast, among patients with no detectable pathogenic TP53 mutation, RIT-CHOP was associated with a longer PFS than with R-CHOP (10-year PFS 67% vs 44%; hazard ratio = 0.49; P = .008). No relationship was detected between PFS and the extent of activation-induced cytidine deaminase (AICDA)-mediated heterogeneity. In summary, subclonal TP53 mutations are common in FL and are a distinct phenomenon from AICDA-mediated genetic heterogeneity. The absence of a detectable subclonal mutation in TP53 defined a population that particularly benefited from RIT.
引用
- Burack WR, Li H, Adlowitz D, et al. Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma. Blood Adv. 2023. PMID: 37379264. doi:10.1182/bloodadvances.2022009467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。